Comparison of the effects of features and classifiers on performance in the cardiovascular disease detection system

Abstract

This study aims to analyze the effects of features and classifiers in detecting cardiovascular diseases (CVD), which remain the leading cause of morbidity and mortality worldwide. Early and accurate detection of CVD significantly affects treatment outcomes. Therefore, the proposed method aims to automatically detect cardiovascular diseases via artificial intelligence. In this research, the performances of artificial intelligence methods for the cardiovascular disease detection problem are analyzed. The dataset used in this study was sourced from the publicly available Kaggle platform. It used for performance analysis in the developed application includes the features of 70000 patients such as age, gender, height, weight, blood pressure, cholesterol, glucose, smoking and alcohol use. These features were classified with Gradient Boosting, XGBoost, SVM, Random Forest, Logistic Regression, Convolutional Neural Network (CNN), Recurrent Neural Network (RNN), Long Short-Term Memory (LSTM) methods and performance comparison was performed. In the experimental results, the highest accuracy rate of 72.55% was obtained using the Gradient Boosting method, demonstrating its superior performance in cardiovascular disease detection. In addition, it was observed that the classification performance decreased when the high blood pressure attribute was removed from the dataset, while the removal of other features did not significantly affect the performance.

Keywords

• Cardiovascular disease (CD)
• Artificial Intelligence
• Detection
• CD risk factors

References

1. [1] Y. Lecun, Y. Bengio, and G. Hinton, “Deep learning,” Nature, vol. 521, no. 7553, pp. 436–444, 2015, doi: 10.1038/nature14539.
2. [2] P. Liu, L. Lin, J. ZHANG, T. HUO, S. LIU, and Z. YE, “Application of Artificial Intelligence in Medicine: An Overview,” Curr. Med. Sci., vol. 41, no. 6, pp. 1105–1115, 2021, doi: https://doi.org/10.1007/s11596-021-2474-3.
3. [3] vA. Shaito et al., “Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety,” Front. Pharmacol., vol. 11, no. April, pp. 1–32, 2020, doi: 10.3389/fphar.2020.00422.
4. [4] E. J. Benjamin et al., Heart Disease and Stroke Statistics’2017 Update: A Report from the American Heart Association, vol. 135, no. 10. 2017.
5. [5] Q. Cheng et al., “Sex-specific risk factors of carotid atherosclerosis progression in a high-risk population of cardiovascular disease,” Clin. Investig., vol. 46, no. 1, pp. 22–31, 2023, doi: 10.1002/clc.23931.
6. [6] A. F. Toronto, L. G. Veasy, and H. R. Warner, “Evaluation of a computer program for diagnosis of congenital heart disease,” Prog. Cardiovasc. Dis., vol. 5, no. 4, p. 1963, 1963.
7. [7] O. I. Al-Sanjary and G. Sulong, “Detection of video forgery: A review of literature,” J. Theor. Appl. Inf. Technol., vol. 74, no. 2, pp. 207–220, 2015.
8. [8] Q. Li et al., “The Prediction Model of Warfarin Individual Maintenance Dose for Patients Undergoing Heart Valve Replacement, Based on the Back Propagation Neural Network,” Clin. Drug Investig., vol. 40, no. 1, pp. 41–53, 2020, doi: 10.1007/s40261-019-00850-0.

9. [9] A. A. Kalinin et al., “Deep learning in pharmacogenomics: From gene regulation to patient stratification,” Pharmacogenomics, vol. 19, no. 7, pp. 629–650, 2018, doi: 10.2217/pgs-2018-0008.
10. [10] G. P. Diller et al., “Machine learning algorithms estimating prognosis and guiding therapy in adult congenital heart disease: Data from a single tertiary centre including 10 019 patients,” Eur. Heart J., vol. 40, no. 13, pp. 1069–1077, 2019, doi: 10.1093/eurheartj/ehy915.
11. [11] I. A. Kakadiaris, M. Vrigkas, A. A. Yen, T. Kuznetsova, M. Budoff, and M. Naghavi, “Machine learning outperforms ACC/AHA CVD risk calculator in MESA,” J. Am. Heart Assoc., vol. 7, no. 22, 2018, doi: 10.1161/JAHA.118.009476.
12. [12] C. P. Cannon, “Mixed Dyslipidemia, Metabolic Syndrome, Diabetes Mellitus, and Cardiovascular Disease: Clinical Implications,” Am. J. Cardiol., vol. 102, no. 12 SUPPL., pp. 5L-9L, 2008, doi: 10.1016/j.amjcard.2008.09.067.
13. [13] R. Huxley, F. Barzi, and M. Woodward, “Excess risk of fatal coronary heart disease associated with diabetes in men and women: Meta-analysis of 37 prospective cohort studies,” Br. Med. J., vol. 332, no. 7533, pp. 73–76, 2006, doi: 10.1136/bmj.38678.389583.7C.
14. [14] H. Chu et al., “Roles of Anxiety and Depression in Predicting Cardiovascular Disease Among Patients With Type 2 Diabetes Mellitus: A Machine Learning Approach,” Front. Psychol., vol. 12, no. April, pp. 1–8, 2021, doi: 10.3389/fpsyg.2021.645418.
15. [15] E. J. Topol, “High-performance medicine: the convergence of human and artificial intelligence,” Nat. Med., vol. 25, no. 1, pp. 44–56, 2019, doi: 10.1038/s41591-018-0300-7.
16. [16] “Skin Cancer: Malignant vs. Benign.” https://www.kaggle.com/datasets/fanconic/skin-cancer-malignant-vs-benign (accessed on).
17. [17] J. H. Friedman, “Greedy Function Approximation: A Gradient Boosting Machine,” Ann. Stat., vol. 29, no. 5, pp. 1189–1232, 2001, doi: 10.1002/9781118445112.stat08190.